(Q34387066)

1 August 2017

title

Individualization of tamoxifen treatment for breast carcinoma (English)

1 reference

1 August 2017

1 reference

L Binkhorst

1

1 reference

1 August 2017

T van Gelder

series ordinal

2

1 reference

1 August 2017

R H J Mathijssen

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

22 August 2012

1 reference

Clinical Pharmacology & Therapeutics

1 August 2017

published in

1 reference

1 August 2017

volume

92

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

431-433

1 reference

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.94

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.94

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.94

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.94

CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.94

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2012.94

1 reference

1 August 2017

1 reference